(+/-)-trans-d8-3-(benzo[1,3]dioxol-5-yloxymethyl)-4-(4-fluorophenyl)-1-methyl-piperidine | 1057327-02-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (+/-)-trans-d8-3-(benzo[1,3]dioxol-5-yloxymethyl)-4-(4-fluorophenyl)-1-methyl-piperidine
• 英文别名: (3S,4R)-2,2,6,6-tetradeuterio-3-[dideuterio-[(2,2-dideuterio-1,3-benzodioxol-5-yl)oxy]methyl]-4-(4-fluorophenyl)-1-methylpiperidine
• CAS: 1057327-02-2
• 化学式: C₂₀H₂₂FNO₃
• 分子量: 351.334
• InChiKey: MOJZPKOBKCXNKG-GNEOTICXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  30.9
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
  申请人：Gant G. Thomas

  公开号：US20070112031A1

  公开（公告）日：2007-05-17

  Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described.

  化学合成和新型单胺神经递质摄取抑制剂的医药用途，以及其药用盐和前药，用于治疗和/或管理精神疾病、焦虑症、广泛性焦虑症、抑郁症、创伤后应激障碍、强迫症、恐慌症、潮热、老年痴呆症、偏头痛、肝肺综合征、慢性疼痛、伤害性疼痛、神经病性疼痛、疼痛性糖尿病视网膜病变、双相抑郁症、阻塞性睡眠呼吸暂停、精神疾病、经前期失调性障碍、社交恐惧症、社交焦虑症、尿失禁、厌食症、暴食症、肥胖症、缺血、头部损伤、脑细胞钙超载、药物依赖和/或早泄。
• SUBSTITUTED PHENYLPIPERIDINES WITH SEROTONINERGIC ACTIVITY AND ENHANCED THERAPEUTIC PROPERTIES
  申请人：Gant Thomas G.

  公开号：US20110130424A1

  公开（公告）日：2011-06-02

  Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described.

  本文描述了新型单胺类神经递质摄取抑制剂及其药用可接受盐和前药的化学合成和医学用途，用于治疗和/或管理精神障碍、焦虑症、广泛性焦虑症、抑郁症、创伤后应激障碍、强迫症、惊恐障碍、潮热、老年性痴呆、偏头痛、肝肺综合征、慢性疼痛、伤害性疼痛、神经性疼痛、疼痛性糖尿病视网膜病变、双相抑郁症、阻塞性睡眠呼吸暂停、精神障碍、月经前期失调症、社交恐惧症、社交焦虑症、尿失禁、厌食症、贪食症、肥胖症、缺血、头部损伤、脑细胞钙超载、药物依赖和/或早泄。